BioNTech revenue and financials
$97.64Change from previous close: +0.76%Absolute change: +$0.74
In the fiscal year ended December 2025, BioNTech reported revenue of €2.87B (+4.32% year over year). The net loss was €1.14B.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +4.32%
- 2025 vs 2024
- Net margin
- -39.6%
- 2024: -24.2%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 21,989 | 22,530 | 23,006 | 23,279 | 15,831 | 2,319 | 798 | 653 | — |
| Current assets | 16,147 | 18,804 | 19,527 | 21,922 | 15,072 | 1,667 | 560 | 449 | — |
| Cash and equivalents | 7,675 | 9,762 | 11,664 | 13,875 | 1,693 | 1,210 | 519 | 412 | 172 |
| Short-term investments | 7,202 | 7,022 | 4,885 | 189 | — | — | — | — | — |
| Receivables | 985 | 1,524 | 2,340 | 7,146 | — | — | — | — | — |
| Inventory | 111 | 283 | 358 | 440 | — | — | — | — | — |
| Net property, plant and equipment | 1,291 | 1,183 | 972 | 821 | — | — | — | — | — |
| Goodwill | 368 | 381 | 363 | 61.2 | 57.8 | 53.7 | 3.0 | — | — |
| Other intangible assets | 1,606 | 790 | 804 | 159 | — | — | — | — | — |
| Long-term investments | 2,554 | 1,254 | 1,176 | 80.2 | — | — | — | — | — |
| Current liabilities | 2,142 | 2,523 | 2,071 | 2,951 | 3,482 | 606 | 138 | 126 | — |
| Accounts payable | 535 | 427 | 354 | 204 | — | — | — | — | — |
| Long-term debt | 215 | 215 | 191 | 176 | — | — | — | — | — |
| Total debt | 267 | 254 | 219 | 212 | — | — | — | — | — |
| Total liabilities | 2,764 | 3,119 | 2,760 | 3,224 | 3,937 | 947 | 304 | 386 | — |
| Total equity (incl. minority) | 19,224 | 19,411 | 20,246 | 20,056 | — | — | — | — | — |
| Retained earnings | 17,962 | 19,098 | 19,763 | 18,833 | — | — | — | — | — |